Literature DB >> 11698416

G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase.

William E Lowry1, Xin-Yun Huang.   

Abstract

G proteins are critical cellular signal transducers for a variety of cell surface receptors. Both alpha and betagamma subunits of G proteins are able to transduce receptor signals. Several direct effect molecules for Gbetagamma subunits have been reported; yet the biochemical mechanism by which Gbetagamma executes its modulatory role is not well understood. We have shown that Gbetagamma could directly increase the kinase activity of Bruton's tyrosine kinase (Btk) whose defects are responsible for X chromosome-linked agammaglobulinemia in patients. The well characterized interaction of Gbetagamma with the PH (pleckstrin homology)/TH (Tec-homology) module of Btk was proposed to be the underlying activation mechanism. Here we show that Gbetagamma also interacts with the catalytic domain of Btk leading to increased kinase activity. Furthermore, we showed that the PH/TH module is required for Gbetagamma-induced membrane translocation of Btk. The membrane anchorage is also dependent on the interaction of Btk with phosphatidylinositol 3,4,5-trisphosphate, the product of phosphoinositide 3-kinase. These data support a dual role for Gbetagamma in the activation of Btk signaling function, namely membrane translocation and direct regulation of Btk catalytic activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698416     DOI: 10.1074/jbc.M110390200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

2.  Identification of dual mechanisms mediating 5-hydroxytryptamine receptor 1F-induced mitochondrial biogenesis.

Authors:  Whitney S Gibbs; Sara M Garrett; Craig C Beeson; Rick G Schnellmann
Journal:  Am J Physiol Renal Physiol       Date:  2017-10-18

3.  Ligand-dependent autophosphorylation of the insulin receptor is positively regulated by Gi-proteins.

Authors:  J Kreuzer; B Nürnberg; H I Krieger-Brauer
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

4.  Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.

Authors:  Anna Turetsky; Eunha Kim; Rainer H Kohler; Miles A Miller; Ralph Weissleder
Journal:  Sci Rep       Date:  2014-04-24       Impact factor: 4.379

5.  Stimulation of Vibratory Urticaria-Associated Adhesion-GPCR, EMR2/ADGRE2, Triggers the NLRP3 Inflammasome Activation Signal in Human Monocytes.

Authors:  Kuan-Yu I; Wen-Yi Tseng; Wen-Chih Wang; Siamon Gordon; Kwai-Fong Ng; Hsi-Hsien Lin
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

Review 6.  Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.

Authors:  Logan Good; Brooke Benner; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2021-04-05       Impact factor: 6.968

Review 7.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.

Authors:  Aqu Alu; Hong Lei; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-10-01       Impact factor: 23.168

Review 8.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

9.  Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.

Authors:  Rebecca Voltan; Erika Rimondi; Elisabetta Melloni; Gian Matteo Rigolin; Fabio Casciano; Maria Vittoria Arcidiacono; Claudio Celeghini; Antonio Cuneo; Giorgio Zauli; Paola Secchiero
Journal:  Oncotarget       Date:  2016-10-25

Review 10.  Role of Bruton's tyrosine kinase in B cells and malignancies.

Authors:  Simar Pal Singh; Floris Dammeijer; Rudi W Hendriks
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.